Abstract
Clostridium difficile infection (CDI) publications have advanced in 2010 at a pace paralleling the increased frequency and severity of clinical infection. Both toxins A and B are essential virulence factors, pcr diagnostic testing is rapid, sensitive and specific, and recurrent CDI can be prevented using monoclonal antibodies to toxins A and B.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Aminoglycosides / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Bacterial Proteins / immunology
-
Bacterial Proteins / physiology
-
Bacterial Toxins / immunology
-
Clostridioides difficile* / genetics
-
DNA, Bacterial / genetics
-
Enterocolitis, Pseudomembranous* / diagnosis
-
Enterocolitis, Pseudomembranous* / drug therapy
-
Enterocolitis, Pseudomembranous* / etiology
-
Enterotoxins / immunology
-
Enterotoxins / physiology
-
Fidaxomicin
-
Humans
-
Reverse Transcriptase Polymerase Chain Reaction
Substances
-
Aminoglycosides
-
Antibodies, Monoclonal
-
Bacterial Proteins
-
Bacterial Toxins
-
DNA, Bacterial
-
Enterotoxins
-
tcdA protein, Clostridium difficile
-
toxB protein, Clostridium difficile
-
Fidaxomicin